JEJason A. Ellis

Jason A. Ellis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jason A. Ellis has a total of 62 co-authors. Here are the top co-authors by number of shared publications:

  • Jeffrey N. Bruce

    Department of Neurological Surgery, Columbia University, New York, NY, USA

    7 shared publications
  • Peter Canoll

    Columbia University Medical Center

    6 shared publications
  • Philip M. Meyers

    Department of Neurological Surgery, Columbia University Medical Center, 710 West 168th Street, New York, NY 10032, USA

    5 shared publications
  • E. Sander Connolly

    Department of Neurological Surgery, Columbia University Medical Center, 710 West 168th Street, New York, NY 10032, USA

    4 shared publications
  • Alfred T. Ogden

    Columbia University Medical Center

    3 shared publications
  • Sean D. Lavine

    Department of Neurological Surgery, Columbia University Medical Center, 710 West 168th Street, New York, NY 10032, USA

    3 shared publications

Latest Publications

  • Staged laser interstitial thermal therapy and topectomy for complete obliteration of complex focal cortical dysplasias

    by Jason A. Ellis, Juan C. Mejia Munne, Shih-Hsiu Wang, Danielle K. McBrian, Cigdem I. Akman, Neil A. Feldstein, Guy M. McKhann


  • Cationizable lipid micelles as vehicles for intraarterial glioma treatment

    by Juliane Nguyen, Johann R. N. Cooke, Jason A. Ellis, Michael Deci, Charles W. Emala, Jeffrey N. Bruce, Irving J. Bigio, Robert M. Straubinger, Shailendra Joshi

    The relative abundance of anionic lipids on the surface of endothelia and on glioma cells suggests a workable strategy for selective drug delivery by utilizing cationic nanoparticles. Furthermore, the extracellular pH of gliomas is relatively acidic suggesting that tumor selectivity could be further enhanced if nanoparticles can be designed to cationize in such an environment. With these motivating hypotheses the objective of this study was to determine whether nanoparticulate (20 nm) micelles could be designed to improve their deposition within gliomas in an animal model. To test this, we performed intra-arterial injection of micelles labeled with an optically quantifiable dye. We observed significantly greater deposition (end-tissue concentration) of cationizable micelles as compared to non-ionizable micelles in the ipsilateral hemisphere of normal brains. More importantly, we noted enhanced deposition of cationizable as compared to non-ionizable micelles in glioma tissue as judged by semiquantitative fluorescence analysis. Micelles were generally able to penetrate to the core of the gliomas tested. Thus we conclude that cationizable micelles may be constructed as vehicles for facilitating glioma-selective delivery of compounds after intraarterial injection.


  • Arteriovenous malformations and headache

    by Jason A. Ellis, Juan C. Mejia Munne, Sean D. Lavine, Philip M. Meyers, E. Sander Connolly, Robert A. Solomon


  • Intraarterial drug delivery for glioblastoma mutiforme

    by Shailendra Joshi, Jason A. Ellis, Eugene Ornstein, Jeffrey N. Bruce

    Intraarterial (IA) drug delivery is a physiologically appealing strategy as drugs are widely distributed throughout the tumor capillary network and high regional tissue concentrations can be achieved with low total doses. IA treatment of glioblastoma multiforme (GBM) has been attempted since the 1950s but success has been elusive. Although IA treatments have been embraced for the treatment of retinoblastoma and advanced liver cancers, this has not been the case for GBM. The development of IA drug delivery for the treatment of brain cancer over the last several decades reveals a number of critical oversights. For example, very few studies took into consideration the underlying hydrodynamic factors. Therapeutic failures were often blamed on an inability to penetrate the blood brain barrier or on the streaming of drugs. Similarly, there were few methods to investigate the ultra-fast pharmacokinetics of IA drugs. Despite past failures, clinical interest in IA drugs for the treatment of GBM persists. The advent of modern imaging methods along with a better understanding of hydrodynamics factors, better appreciation of the complex morphology of GBM, improved drug selection and formulations, and development of methods to minimize treatment-related neurological injury, promise to considerably advance the application of IA drugs for GBM treatment. There are several clinical trials with IA treatments in the National Trial Registry that are actively recruiting patients. This review of IA drug delivery for GBM treatment is therefore timely and is intended to assess how this method of drug delivery could be better applied to future treatments.


  • Open Access

    Subarachnoid hemorrhage then thrombosis of posterior inferior cerebellar artery dissection: is early surgical exploration warranted?

    by Nikita G Alexiades, Jason A Ellis, Philip M Meyers, E Sander Connolly

    The natural history of spontaneous cerebral artery dissection and thrombosis remains uncertain. Concurrent subarachnoid hemorrhage further complicates the therapeutic approach. Thus the best strategy for managing patients with acute vessel thrombosis in the setting of subarachnoid hemorrhage is unclear. Here we present a case of spontaneous posterior inferior cerebellar artery dissection presenting with subarachnoid hemorrhage and acute thrombosis. Although the patient was initially managed conservatively, angiographic follow-up demonstrated recanalization of the diseased vessel, necessitating definitive treatment. Thus we propose that angiographic follow-up is necessary in the management of patients with subarachnoid hemorrhage in association with apparent vessel thrombosis.

  • Unique microenvironmental responses to PDGF stimulation in brain and spinal cord gliomas determine tumor phenotype

    by Jason A. Ellis, Michael Castelli, Marcela Assanah, Jeffrey N. Bruce, Peter Canoll, Alfred T. Ogden

    Injection of a PDGF-B expressing retrovirus into the subcortical white matter of adult rats induces the rapid formation of brain tumors that have the histological features of glioblastoma. In contrast, when the same retrovirus is injected into the spinal cord of adult rats the resulting tumors are more indolent and display a unique histology characterized by nests of tumor cells separated by a dense vascular network without areas of necrosis. To study whether these differences are determined by the tumor cell of origin or due to microenvironmental influences, we conducted a series of transplantation experiments. Cells were independently isolated from PDGF-induced brain and cord tumors then subsequently transplanted into naive rat forebrains and spinal cords. The resulting tumors were characterized by histological analysis, marker expression profiling, PDGFR subtyping, and latency to tumor-induced morbidity. Tumor phenotypes were found to be consistently predicted by the tissue into which they were transplanted rather than by the tissue of origin. These results suggest that tumor microenvironment rather than the tumor cell of origin may be the primary determinant of glioma phenotype in the model presented.


  • Superficial Temporal Artery Pseudoaneurysm Following Trigeminal Nerve Stimulator Placement

    by Jason A. Ellis, Brian J. Gill, David Pisapia, Christopher J. Winfree


  • The Role of Antiplatelet Medications in Angiogram-Negative Subarachnoid Hemorrhage

    by Jason A. Ellis, Michael M. McDowell, Stephan A. Mayer, Sean D. Lavine, Philip M. Meyers, E. Sander Connolly

    The use of antiplatelet medications has greatly expanded and this has been associated with an increased rate of complications after aneurysmal subarachnoid hemorrhage (SAH). The influence of antiplatelet medications on outcomes after non-aneurysmal SAH is unknown. To analyze the frequency and impact on outcome of antiplatelet medication use among patients with angiogram-negative SAH. An analysis of patients within the Columbia University SAH Outcomes Project database was performed. All patients who underwent catheter cerebral angiography after presenting with nontraumatic SAH between 1996 and 2013 were included. Outcomes were assessed by using the modified Rankin Scale. A total of 1351 patients underwent catheter angiography for evaluation of SAH. Of these, 173 (13%) were designated angiogram-negative. The fraction of patients presenting with angiogram-negative SAH as well as the frequency of antiplatelet use among these patients significantly increased during the study period. Antiplatelet use was more commonly associated with angiogram-negative SAH than with angiogram-positive SAH (27% vs 14%, P = .001). At 14 days after presentation, poor outcome was significantly more frequent among patients who took antiplatelet agents than among those who did not (38% vs 20%, P = .017). This effect was also seen after multivariate analysis (odds ratio, 2.58; P = .034), although no difference was observed by 12 months (P > .05). Antiplatelet medication use is associated with poor early, but not late, outcomes after angiogram-negative SAH. Corresponding increased rates of antiplatelet medication use and angiogram-negative SAH may be related. Additional studies are needed to confirm this association.


  • Post-subarachnoid Hemorrhage Vasospasm in Patients with Primary Headache Disorders

    by Jason A. Ellis, Hannah Goldstein, Philip M. Meyers, Sean D. Lavine, E. Sander Connolly, Stephan A. Mayer, Neeraj Badjatia, Dorothea Altschul

    Altered cerebral vasomotor reactivity leading to vasospasm can be seen both in patients with primary headache disorders (PHD) and in patients with subarachnoid hemorrhage (SAH). The pathogenesis of vasospasm in post-SAH patients and in headache disorder sufferers may be related. To address this hypothesis, we analyzed a large cohort of SAH patients to determine whether a diagnosis of PHD predisposes to vasospasm, delayed cerebral ischemia, or worsened clinical outcome.


  • Epithelioid Pituicytoma

    by Jason A. Ellis, Nadejda M. Tsankova, Randy D'AMico, John C. Ausiello, Peter Canoll, Marc K. Rosenblum, Jeffrey N. Bruce